Obesity as an Important Risk Factor for Certain Types of Cancer

Sayed Hassan Davoodi 1, Talieh Malek-Shahabi 2, Ali Malekshahi-Moghadam 3, Roghieh Shahbazi 1, Saeideh Esmaeili 4

Abstract

Cancer could be described as the uncontrolled and unrestricted growth of malignant cells in any place of the body. It is a multifactorial disease which either heredity or environmental factors (such as nutrition, physical inactivity, alcohol, obesity, exposure to sun, environmental pollutants, infections) chip in incidence of cancer. In recent years, several researchers have focused on obesity as a potent cancer risk factor. Scientific evidences have suggested that obesity has associated with increased risk for a plenty of different types of cancer. The evidences are the most consistent for endometrial cancer, breast cancer between the postmenopausal women, and renal cell cancer. More contradictory results have reported about the colorectal, prostate, and pancreatic cancer. Although numerous studies have done according to the obesity and cancer relation or joint, but The molecular mechanisms in which obesity could increase the risks of cancer, have been poorly understood.

Keywords: Neoplasms; Obesity; Adipocyte; Adipokines; Adiponectin

Introduction

Cancer is a dynamic and long-term process which could be considered as a group of diseases with at least this common characteristic: uncontrolled and invasive cell growth and proliferation [1]. Cancer has occurred when cell proliferation has been more than cell death, leading to an unrestricted division, then expanding of malignant cells in the body [2, 3].

Cancer is one of the most defined concerns of global health, as well as one of the most major cause of death, all over the world. It has accounted for more than 7 million deaths each year. Both genetic and environmental factors chip in the incidence and development of cancer. However genetic defects could approximately be responsible for 10% of the all cases of cancer, the environmental factors have comprised approximately 90%. The most important environmental risk factors of cancer, have included lifestyle associated factors (smoking, alcohol, nutrition and dietary habits, sedentary lifestyle, obesity, and excessive exposure to sunlight) as well as pollution, then viral and bacterial infection [4, 5].

Obesity is excess accumulation of adipose tissue in the body. It occurs when energy intake is more than energy expenditure within a long period of time. Obesity has regarded as a multifactorial disorder with a complex phenotype. Genetics and lifestyle-dependent factors (long-term excess energy intake more than body requirement and physical inactivity) could be the main obesity determinant. Of course the other causes of obesity social factors and metabolic and neuroendocrine alterations should be mentioned [6-8]. The ability of storing calories in the form of adipose tissue was a crucial feature for human to survive during nutritional deprivation conditions [6]. But unfortunately today obesity has become epidemic in developed world [9] also in many developing countries [10].

Obesity correlates with the incidence of various chronic diseases especially some types of cancer.
Obesity as an Important Risk Factor for Certain Types of Cancer

But this relation has appeared differently, because nowadays together with the rapid increase rate of children obesity prevalence, the risk of cancer incidence would be increased in their adulthood [12].

Recently, many investigators have been studying the impact of obesity on cancer. The findings of the research were inconsistent even among the patients whose suffering from the same cancer due to the cancer stage or cancer grade and diagnosis period of time [3]. This article has reviewed the effect of obesity on the risk of the cancer incidence and prevalence, then the probable mechanisms. The effects of obesity on cancer risks have described as below and in Figure 1.

Table 1 has indicated selective publications on the relations between the obesity with cancer.

![Figure 1. It shows the obesity and cancer relationship.](image)

**Table 1. Selected publications on obesity and cancers relationship**

| Type of cancer            | Mechanisms                                                                 | References |
|---------------------------|-----------------------------------------------------------------------------|------------|
| Renal cell carcinoma      | - Obesity cause to increased level of estrogen that effects on growth and proliferation of renal cells. | [71]       |
| Colorectal cancer         | - Steroid hormones<br>- Chronic inflammation                               | [70, 65]   |
| Breast cancer             | - Decrease of sex hormone-binding globulin<br>- Hormonal factors             | [63, 64]   |
| Pancreatic cancer         | - Chronic inflammation<br>- Hormonal factors                                 | [70, 56]   |
| Prostate cancer           | - In obesity endogenous estrogen and progesterone increases and cause to inhibition of prostate cancer growth and metastasis. | [54, 55]   |
| Endometrial cancer        | - Decrease of sex hormone-binding globulin<br>- Hormonal factors             | [50, 51]   |

**Properties of Adipose Tissue**

Adipose tissue is a heterogeneous organ which consists of various types of cells. This tissue divided to White Adipose Tissue (WAT) and Brown Adipose Tissue (BAT), with different functions. WAT has located in subcutaneous layer, omentum and retroperitoneum. This adipose tissue mainly has considered as an energy reservoir which stores excess body energy in the form of triglyceride and increased during obesity. BAT has found in cervical and supra cervical, and adipose of energy through thermogenesis. Both two types has divided to adipocytes and stromal-vascular section. Adipocyte has included of lipid-laden adipocyte and the stromal-vascular section including preadipocyte, endothelial cells and macrophage.
and other immune cells. All types of cells in both sections could altered the metabolic hemostasis of the organ. So changes in the biology of adipocyte or non-adipocyte (in stromal-vascular section) could increased the risk of cancer in obesity [6, 13, 14].

Effects of Increased Adipose Tissue

Adipose tissues possess two main roles in the body [3]: storing excess calories as lipid [6], and having active role in endocrine signaling to other sites of the body [6, 13, 14].

Previous studies have shown that adipose tissues have secreted molecules signaling to the other metabolic organs and brain [15]. Probably some of these molecules have possessed a role in modulating the risk of cancer development (adipokines molecules such as leptin, adiponectin, proinflammatory molecules) [6].

Size and number of adipocyte cells have increased in obesity. These changes in adipose tissue have increased the leptin and inflammatory cytokine levels, and then have reduced the adiponectin secretion [6]. Below we have discussed some of the effects of adipokines and inflammatory cytokine on cancer:

Secreted Molecules From Adipose Tissue Inflammatory Cytokines

Inflammatory cytokines were the first polypeptides which have revealed from adipose tissue. They have exerted a systemic role in metabolic hemostasis. In vitro and in vivo research has shown the levels of the inflammatory cytokines such as Tumor Necrosis Factor-α (TNFα), Interleukin-6 (IL-6), and Plasminogen Activator Inhibitor-1 (PAI-1) raise obesity [16].

Actually these cytokines have secreted by monocytes [17] and other immune cells. These immune cells have infiltrated adipose tissue in obesity [18]. The increased cytokines have caused chronic inflammation, which this inflammation has correlated with cancer incidence through various mechanisms [19].

TNF-α and Cancers

TNF-α is a cytokine that has been known as a modulator in endotoxin-induced tumor necrosis [20]. It has related to incidence and development of various cancers through activation of angiogenesis and metastasis [21, 22]. TNFα is necessary for azoxymethane-induced colon carcinogenesis also chemically induced skin and liver carcinogenesis [23-25]. The increased TNFα levels in obese rodent and humans have shown relation between obesity and tumor genesis [26, 27]. Removing TNFα signaling by deletion of its receptor gene has abrogated the ability of high-fat diet to promote liver carcinogenesis [28]. In contrast, removing this receptor in lean mice has not caused any effect on liver carcinogenesis [29]. This data has outstand the importance of relation between TNFα in obesity and cancers.

IL-6 and Cancer

One of the major pro-inflammatory molecules that has produced in adipose tissue is the cytokine IL-6 [30]. Circulating IL-6 levels has correlated with BMI [31], and adipose tissue has thought to account for up to 35% of circulating IL-6 in healthy subjects [32].

IL-6 has sent signals to nucleus through STAT3. IL-6 could bind to interleukin-6 (IL-6) receptor, and could activate JAK-Stat and Activator of Transcription (STAT) signaling through STAT3 [6]. STAT3 was an oncoprotein which could be important in cancers risk [33]. The activation of STAT3 has increased in tumors that have grown in obese animals [28].

PAI-1 and Cancer

PAI1 is the primary inhibitor of the plasminogen activators urokinase and tissue plasminogen activator, and has been produced at high levels in adipose tissue. Plasminogen is the precursor of the extracellular protease plasmin, and is a key component for metastasis and angiogenesis [34, 35]. Activation of plasminogen might result to increased extracellular remodeling, which is a key process in cancer development [36, 37]. High levels of PAI-1 have correlated with poor outcome in breast cancer in human [38]. PAI-1 inhibitors could decrease risk of polyp formation in Adenomatous Polyposis Coli (APC) mice [39]. Increased expression of PAI1 in obesity might increase the vascularization and invasiveness of tumors, although this has not been formally demonstrated [6].

Leptin and Cancer

Leptin is an adipocyte-derived hormone that regulates appetite and energy homeostasis [40]. Several studies have shown Leptin Receptors (LEPR) expressed in several cancers like prostate, breast and colon [41-43]. Leptin levels have correlated with obesity in human [44]. Previous studies have demonstrated that this hormone has related to
increased incidence of cancer in obesity [6]. Many studies on leptin and cancer relation have shown different results. For example in an analysis of Greek men, after adjusting for Body Mass Index (BMI), leptin has not correlated with prostate cancer incident [45].

The results of a large scale study in Scandinavian men have shown relation between leptin levels and prostate cancer risk, although this was accurate for intermediate levels, but not at all for the higher levels [46].

Also the results of a regression analysis of women in Massachusetts, USA have shown that leptin has not associated with increased carcinoma in situ of the breast [47]. By contrast, the results of analysis of Japanese women with colorectal cancer have indicated that leptin has associated with increased risk, independently of BMI [48]. Leptin has caused stimulation growth of colonic epithelial cells, cancer cells in breast, prostate and ovary [49-52].

**Adiponectin and Cancer**

Adiponectin is another adipokine that might have a role in cancer. Adiponectin levels have reduced in obesity. Adiponectin acts on a number of tissues to regulate glucose and lipid metabolism [53]. Several studies have suggested that adiponectin had antitumor effects [6].

Adiponectin secreted from adipocytes has bound to its own receptors (ADIPOR1 and ADIPOR2), and inhibits proliferation and metastasis. Adiponectin has increased the conversion of ceramide to sphingosine-1-phosphate, which had a variety of effects on apoptosis and insulin resistance, possibly via AMP-Activated Kinase (AMPK) [6]. Prospective analyses have shown adiponectin levels have inversely associated with breast cancer risk in postmenopausal women [54]; endometrial and renal cell carcinoma [55].

However in later prospective study, adiponectin levels were not predictive for the endometrial cancer risk [56]. The results of study have shown that using a case-control design, a Single Nucleotide Polymorphism (SNP) in the 5’ region of adiponectin has been found in association with colorectal cancer risk [57].

**Relation Between Obesity and Cancers**

**Endometrial Cancer**

The relation between obesity and endometrial cancer was obvious in both case-control and follow-up studies particularly in postmenopausal women [58,59]. For example, a case-control study about the prevalence of obesity on women affected with this malignant tumor in Mexico City has shown this relation [60, 61]. The results have demonstrated that obesity has occurred in 77 % (Odds Ratio [OR] 8.1, 95% Confidence Interval [CI] 2.46-26.6); diabetes mellitus in 41 % (OR:4.3, CI:1.31-14.7); and systemic arterial hypertension in 41% (OR: 2.3, CI: 0.78-7.1). So, they have concluded that obesity was the most frequent risk factor for these women with endometrial cancer [61].

These relations have based on hormones. Endometrial epithelial cells has stimulated by high levels of estrogen. This stimulation has not suppressed by progesterone and so, it has caused to cancer [62].

Obese women had more levels of estrogen and estradiol in their serum [63]. This was because of aromatization of androstenedione in the adipose tissue. Also, obese women had lower levels of sex hormone-binding globulin so estrogen levels increase [64].

**Prostate Cancer**

According to previous studies, there is a positive but weak association between obesity and prostate cancer. For example, the results of meta analyses have demonstrated the relation between BMI and weight and moderately increased risk of advanced disease but there was low association with risk of localized disease. Although this results has seen about weight just among cohort studies [65].

In addition, Swedish workers studies have shown the positive association between BMI and weight and risk of prostate cancer [66]. In a prospective study, in Japanese-American men have shown positive relation between prostate cancer and muscle area, not fat area [67].

In obesity, endogenous estrogen and progesterone have increased, then caused to inhibition of prostate cancer growth and metastasis. So, obese men with prostate cancer had better prognosis than those with normal weight [68].

**Pancreatic Cancer**

There is a positive relation between obesity and pancreatic cancer. For example, the meta analysis of 21 prospective studies have reported a relative risk of pancreatic cancer per 5-unit increased in BMI of 1.16 in men and 1.10 in women [69]. In a case-control study, there were positive correlation between overweight (BMI: 25-29.9) and obese
individuals (BMI>30) and risk of pancreatic cancer [70]. Also, the results of several studies have shown the relation between obesity and pancreatic cancer [71, 72].

Obesity is one of the few modifiable risk factors that has associated with increased risk of pancreatic cancer, which has related to increased risk of diabetes, a condition which has been associated with pancreatic cancer development. The recent data has shown that nearly 70% of United States adults are overweight or obese, a clarification of the complex association between obesity and pancreatic cancer might disclose targets for prevention and intervention to decrease incidence and improve prognosis of this highly fatal disease [71].

In one population-based case-control study in Urban Shanghai, 908 patients with pancreatic cancer and 1067 normal controls, aged 35-79 years, have recruited. The results have demonstrated that energy density has positively associated with pancreatic cancer risk (OR: 1.16 per unit increase; 95% CI: 1.07, 1.27; P < 0.001). In this case-control study, dietary energy density has positively associated with risk of pancreatic cancer [72].

**Breast Cancer**

Several studies have shown that obesity increases risk of breast cancer especially in postmenopausal women [73]. For example, the results of a study in women from 7 different countries have shown risk of breast cancer increased with body mass, in low and moderate-risk countries, among premenopausal women, but in postmenopausal women the risk increased in all groups [74]. Probably breast cancer has affected by distribution of body fat. When central adiposity increases, the risk of breast cancer has increased in postmenopausal women particularly when there is a family history of breast cancer [75].

Also, breast cancer patients had more visceral fat compare to subcutaneous fat than control groups [76]. In several studies it has approved that increasing of body mass correlated with poorer survival [77].

Breast cancer has strongly affected by hormonal factors. Diversities in metabolism of steroid hormone cause to different effects on obesity and breast cancer in pre- and postmenopausal women [75]. Before menopause, ovaries are the main source of production of estrogen and after menopause secretion of estrogen has reduced. Instead of that, estrogen has produced in adipose tissue (because of aromatization of androstenedione). This happening is important in obese people. Other factors like decrease of sex hormone-binding globulin enhance risk of breast cancer [78].

Breast cancer would be initiated from epithelial tissue in mammary. Because this tissue is near to adipose tissue of mammary gland, which influence each other [79].

**Colorectal Cancer**

Many studies have shown changes in regulation of energy hemostasis has related to colorectal carcinoma. There is positive relation between increase in body size and colorectal cancer [80]. Colon and rectum cancer have considered together as a colorectal cancer, but rectum and colon were different in some properties [81]. So they should be studied separately.

The results of study have shown an increase of 25% in body weight has associated with rectum cancer in men and women but correlated with colon cancer just in men [82]. Although BMI has correlated with risk of colonic adenomas positively in both men and women, but it has not related to rectal adenomas in women. Also waist circumference and waist-to-hip ratio have related to colon adenomas in men [83]. In addition, another study has shown an increase in the risk of colon cancer in person who had unfavorable energy balance, physically inactive, more energy intakes, and large BMI [84].

In general, men have greater risk for colorectal cancer in comparison to women, because men have possessed greater tendency to store fat in abdomen than women [85].

**Renal Cell Carcinoma**

Various studies have indicated that renal cell carcinoma has associated with obesity [86-88]. According to epidemiological studies, obesity is an effective risk factor of renal cell cancer [86].

The results of cohort study which have analyzed 592 men and 263 women with renal cell cancer, during a median follow-up of 10 years, have shown high levels of BMI among men and women have associated with increased risk of renal cell cancer [87]. A case-control study and a multicenter study have shown body weight strongly affected on renal cancer particularly in women in comparison to men. This strong relation among women has resulted from increased level of estrogen which affect growth and proliferation of renal cells by
Conclusion
The increasing prevalence of obesity in many parts of the world has emphasized the importance of learning more about the relationship between obesity and cancer and the mechanisms involved in their interaction which have reviewed in this article.

In conclusion, obesity has associated with increased risk for different types of cancer. The evidence has been most consistent for endometrial cancer, breast cancer in postmenopausal women, and renal cell cancer. More variable results have reported for colorectal, prostate and pancreatic cancer.

Possible mechanisms which have affected in association of obesity and risk of cancers include alteration in hormonal patterns such as sex hormones and distribution of fat in body. The evidence has suggested that combination of factors which have secreted by the adipocyte, such as increasing leptin, decreasing adiponectin receptors of renal cells or through paracrine growth factors [89].

Acknowledgment
This manuscript has just cited a selected number of articles. Therefore, I appreciate all researchers in this field, also I thank Dr Ali Ardekani (Department of Reproductive Genetics and Biotechnology, Shahid Beheshti University, Tehran, Iran) for his kind advise in this subject.

Conflict of Interest
The authors have no conflict of interest in this article.

Authors’ Contribution
This article has written in collaboration between all authors. Dr Sayed Hossain Davoodi and Saeideh Esmaeii have designed and revised the study. Talieh Malek-Shahabi has contributed to the literature review and writing-up process. Dr Ali Malekshahi-Moghadam and Roghieh Shahbazi have helped in writing and overall correction of the manuscript. All authors have read and approved it finally.

References
1. Chial H. Genetic regulation of cancer. Nature Education. 2008.
2. Pan MH, Gaih G, Ho CT. Food bioactive, apoptosis and cancer. Mol Nutr Food Res. 2008; 52(1): 43-52.
3. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000; 100: 57–70.
4. La Vecchia C, Negri E, D’Avanzo B, Boyle P, Franceschi S. Dietary indicators of oral and pharyngeal cancer. Int J Epidemiol. 1991; 20(1): 39-44.
5. Davoodi SH, Esmaeii S, Mortazaviam AM. Effects of milk and milk products consumption on cancer: A review. Compr Rev Food Sci Food Safety. 2013; 12(3): 249-64.
6. Khandekar MJ, Cohen P, Spiegelman BM. Molecular mechanisms of cancer development in obesity. Nat Rev Cancer. 2011; 11 (12): 886-95.
7. Marti A, Moreno-Aliaga MJ, Hebebrand J, Martinez JA. Genes, lifestyles and obesity. Int J Obes Relat Metab Disord. 2004; 28 (Suppl 3): 29-36.
8. John PH, Wilding JM. Causes of obesity. Practical Diabetes Int. 2001; 18(6): 288-92.
9. Flegal KM, Carroll MD, Ogden CL, Curtin LR. Prevalence and trends in obesity among US adults, 1999-2008. JAMA. 2010; 303 (3): 235-41.
10. Finucane M, Stevens GA, Cowan MJ, Danaei G, Lin JK, Paciorek CJ, et al. National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9.1 million participants. Lancet. 2011; 377 (9765): 557-67.
11. Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet. 2008; 371 (9612): 569-78.
12. Jeffreys M, Smith GD, Martin RM, Frankel S, Gunnell D. Childhood body mass index and later cancer risk: a 50-year follow-up of the Boyd Orr study. Int J Cancer. 2004; 112 (2): 348-51.
13. Bjorndal B, Burri L, Staalesen V, Skorve J, Berge RK. Different Adipose Depots: Their Role in the Development of Metabolic Syndrome and Mitochondrial Response to Hypolipidemic Agents. J Obes. 2011; 2011: 490-650.
14. Shen W, Wang Z, Pujanita M, Lei J, Sinav A, Kral JG, et al. Adipose tissue quantification by imaging methods a proposed classification. Adipose tissue as an endocrine and paracrine organ. Obes Res. 2003; 11(1): 5-16.
15. Mohamed-Ali V, Pinkney JH, Coppack SW. Adipose tissue as an endocrine and paracrine organ. Int J Obes Relat Metab Disord. 1998; 22(12): 1145-58.
16. Fajn JN. Release of interleukins and other inflammatory cytokines by human adipose tissue is enhanced in obesity and primarily due to the nonfat cells. Vitam Horm. 2006;74: 443-77.
17. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW, et al. Obesity is associated
with macrophage accumulation in adipose tissue. J Clin Invest. 2003; 112 (12): 1796-1808.

18. Ruan H, Zarnowski MJ, Cushman SW, Lodish HF. Standard isolation of primary adipose cells from mouse epididymal fat pads induces inflammatory mediators and down-regulates adipocyte genes. J Biol Chem. 2003; 278 (48): 47585-93.

19. Grivennikov SI, Greten FR, Karin M. Immunity, inflammation, and cancer. Cell. 2010; 140 (6): 883-99.

20. Carswell EA, Old LJ, Kassel RL, Green S, Fiore N, Williamson B. An endotoxin-induced factor that causes necrosis of tumors. Proc Natl Acad Sci USA. 1975; 72 (9): 3666-70.

21. Leibovich S, Polverini PJ, Shepard HM, Wiseman DM, Shively V, Nuseir N. Macrophage-induced angiogenesis is mediated by tumor necrosis factor-alpha. Nature. 1987; 329 (6140): 630-2.

22. Oroz P, Echtenacher, Falk W, Ruschoff J, Weber D, Mannel DN. Enhancement of experimental metastasis by tumor necrosis factor. J Exp Med. 1993; 177 (5): 1391-8.

23. Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Blocking TNF-alpha in mice reduces colorectal carcinogenesis associated with chronic colitis. J Clin Invest. 2008; 118 (2): 560-70.

24. Moore RJ, Owens DM, Stamp G, Arnott C, Burke F, East N, et al. Mice deficient in tumor necrosis factor-alpha are resistant to skin carcinogenesis. Nat Med. 1999; 5 (7): 828-31.

25. Knight BB, Yeoh GCT, Husk KL, Ly T, Abraham RJ, Owens DM, Stamp G, Arnott C, Kern PA, Ranganathan S, Li C, Wood L, Popivanova BK, Kitamura K, Wu Y, Kondo T, Kagaya T, Kaneko S, et al. Impaired pre neoplastic changes and Start16 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001; 280: E745-51.

26. Jain SS, Bird RP. Elevated expression of tumor necrosis factor-alpha signaling molecules in colonic tumors of Zucker obese (fa/fa) rats. Int J Cancer. 2010; 127 (9): 2042-50.

27. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001; 280: E745-51.

28. Park Ej, Lee JH, Yu GY, He G, Ali SR, Holzer RG, et al. Dietary and genetic obesity promote liver inflammation and tumor genesis by enhancing IL-6 and TNF expression. Cell. 2010; 140 (2): 197-208.

29. Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Sci. 2007; 317 (5834): 121-4.

30. Fried SK, Bunkin DA, Greenberg AS. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J Clin Endocrinol Metab. 1998; 83 (3): 847-50.

31. Kern PA, Ranganathan S, Li C, Wood L, Ranganathan G. Adipose tissue tumor necrosis factor and interleukin-6 expression in human obesity and insulin resistance. Am J Physiol Endocrinol Metab. 2001; 280: 745-51.

32. Mohamed-Ali V, Goodrich S, Rawesh A, Katz DR, Miles JM, Yudkin JS, et al. Subcutaneous adipose tissue releases interleukin-6, but not tumor necrosis factor-alpha, in vivo. J Clin Endocrinol Metab. 1997; 82(12): 4196-200.

33. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao y, Pestell RG, Albanese C, et al. Stat3 as an oncogene. Cell. 1999; 98 (3): 295-303.

34. Dano K, Behrendt N, Hoyer-Hansen G, Johnsen M, Lund LR, Ploug M, et al. Plasminogen activation and cancer. Thromb Hemost. 2005; 93(4): 76-81.

35. Ferrara N. Binding to the extracellular matrix and proteolytic processing: two key mechanisms regulating vascular endothelial growth factor action. Mol Biol Cell. 2010; 21 (5): 687-90.

36. Egeland M, Nakasone ES, Werb Z. Tumors as organs: complex tissues that interface with the entire organism. Dev Cell. 2010; 18 (6): 884-901.

37. Sawdey MS, Loskutoff, DJ. Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991; 88 (4): 1346-53.

38. Fokeks JA, Schmitt M, Putten WLV, Peters HA, Kramer MD, Janicke F, et al. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994; 12 (8): 1648-58.

39. Mutoh M, Niho N, Komiya M, Takahashi M, Ohtsubo R, Nakatogawa K, et al. Plasminogen activator inhibitor-1 (Pai-1) blockers suppress intestinal polypl formation in Min. mice. Carcinog. 2008; 29 (4): 824-9.

40. Cohen P, Zhao C, Cai X, Montez JM, Rohani SC, Feinstein P, et al. Selective deletion of leptin receptor in neurons leads to obesity. J Clin Invest. 2001; 108 (8): 1113-21.

41. Jarde T, Perrier S, Vasson M P, Caldefie-Chezet F. Molecular mechanisms of leptin and adiponectin in breast cancer. Eur J Cancer. 2011; 47 (1): 33-43.

42. Snousi K, Storsberg AD, Bouaquina N, Ben Ahmed S, Helal AN, Chouchan M. Leptin and leptin receptor polymorphisms are associated with increased risk and poor prognosis of breast carcinoma. BMC Cancer. 2006; 6: 38.

43. Howard JM, Pidgeon GP, Reynolds JV. Leptin and gastro-intestinal malignancies. Obes Rev. 2010; 11 (12): 863-74.

44. Maffei M, Halaas J, Ravussin E, Pratley RE, Lee YP, Zhang Y, et al. Leptin levels in human and rodent: measurement of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med. 1995; 1 (11): 1155-61.

45. Lagiou P, Signorello LB, Trichopoulos D, Taoumou A, Mantzoros CS. Leptin in relation to prostate cancer and benign prostatic hyperplasia. Int J Cancer. 1998; 76 (1): 25-8.
46. Statin P, Soderberg S, Hallmans G, Bylund A, Kaaks R, Stenman U, et al. Leptin is associated with increased prostate cancer risk: a nested case-referent study. J Clin Endocrinol Metab. 2001; 86 (3): 1341-5.

47. Mantzoros CS, Bolhke K, Moschos S, Cramer DW. Leptin in relation to carcinoma in situ of the breast: a study of pre-menopausal cases and controls. Int J Cancer. 1999; 80 (4): 523-6.

48. Tamakoshi K, Toyoshima H, Waki K, Kojima M, Suzuki K, Watanabe Y, et al. Leptin is associated with an increased female colorectal cancer risk: a nested case-control study in Japan. Oncol. 2005; 68 (4-6): 454-61.

49. Hardwick JC, Van Den Brink GR, Offerhaus GJ, Van Deventer SJ, Peppelenbosch MP. Leptin is a growth factor for colonic epithelial cells. Gastroenterol. 2001; 121 (1): 79-90.

50. Dieuonne MN, Machinal-Quelin F, Seazin-Ieroy V, Leneuve MC, Pecquery R, Giudicelli Y. Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun. 2002; 293 (1): 622-8.

51. Onuma M, Bub JD, Rummel TL, Iwamoto Y. Prostate cancer cell-adipocyte interaction: leptin mediates androgen-independent prostate cancer cell proliferation through c-Jun NH2-terminal kinase. J Biol Chem. 2003 (43): 278; 42660-7.

52. Choi JH, Park SH, Leung PC, Choi KC. Expression of leptin receptors and potential effects of leptin on the cell growth and activation of mitogen-activated protein kinases in ovarian cancer cells. J Clin Endocrinol Metab. 2005; 90 (1): 207-10.

53. Hu E, Liang P, Spiegelman BM. AdipoQ is a novel adipose-specific gene deregulated in obesity. J Biol Chem. 1996; 271 (18): 10697-703.

54. Tworoger SS, Heater Eliassen A, Kelesidis T, Colditz GA, Willett WC, Mantzoros CS, et al. Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab. 2007; 92 (4): 1510-6.

55. Cust AE, Kaaks R, Friedenreich C, Bonnet F, Laville M, Lukanova A, et al. Plasma adiponectin levels and endometrial cancer risk in pre- and postmenopausal women. J Clin Endocrinol Metab. 2007; 92 (1): 255-63.

56. Salimian PT, Cui X, Zhang Q, Hankinson SE, Lu KH. Circulating adiponectin levels and risk of endometrial cancer: the prospective Nurses' Health Study. Am J Obstet Gynecol. 2011; 204 (2): 167 e1-e5.

57. Kaklamani VG, Wisinski KB, Sadim M, Gulden C, Do A, Offit K, et al. Variants of the adiponectin (ADIPQ) and adiponectin receptor 1 (ADIPOR1) genes and colorectal cancer risk. JAMA. 2008; 300 (1): 1523-31.

58. Hill HA, Austin H. Nutrition and Endometrial Cancer. Cancer Cause Control. 1996; 7 (1): 19-32.

59. Tornberg SA, Carstensen JM. Relationship Between Quetelet's Index and Cancer of Breast and Female Genital Tract in 47,000 Women followed for 25 Years. Br J Cancer. 1994; 69 (2): 358-61.

60. Senz-chavez TL, Vilar-compete D, De nicola-Delfin L, Meneses-Garcia A. Overweight, obesity, diabetes, and hypertension in endometrial cancer. Rev Med Inst Mex Seguro Soc. 2013; 51 (3): 326-9.

61. Ortiz-Mendoza CM, Velasco-Navarro C. Obesity, a main risk factor for endometrial cancer. Rev Med Inst Mex Seguro Soc. 2013; 51 (3): 260-3.

62. Key TJ. Hormones and Cancer in Humans. Mutat Res. 1995; 333 (1-2): 59-67.

63. Folsom AR, Kaye SA, Potter JD, Prineas RJ. Association of Incident Carcinoma of the Endometrium with Body Weight and Fat Distribution in Older Women. Early Findings of the Iowa Women's Health Study. Cancer Res. 1989; 49 (23): 6828-31.

64. MacDonald PC, Sitteri PK. The Relationship Between the Extra glandular Production of Estrone and the Occurrence of Endometrial Neoplasia. Gynecol Oncol. 1974; 2 (2-3): 259-63.

65. Macniss RJ, English DR. Body size and composition and prostate cancer risk: systematic review and meta-regression analysis. Cancer Cause Control. 2006; 17 (8): 989-1003.

66. Andersson SO, Wolk A, Bergelström R, Adami HO, Engholm G, Englund A, Nyren O. Body Size and Prostate Cancer: A 20-year Follow-up Study Among 135,006 Swedish Construction Workers. J Natl Cancer Inst. 1997; 89 (5): 385-9.

67. Severson RK, Grove JS, Nomura AMY, Steimerman GN. Body Mass and Prostatic Cancer: a Prospective Study. Br Med J. 1988; 297 (6650): 713-5.

68. Daniell HW. A Better Prognosis for Obese Men with Prostate Cancer. J Urol. 1996; 155 (1): 220-5.

69. Larsson SC, Orsini N, Wolk A. Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. Int J Cancer. 2007; 120 (9): 1993-8.

70. Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. Body Mass Index and Risk, Age of Onset, and Survival in Patients with Pancreatic Cancer. AMA. 2009; 301 (24): 2553-62.

71. Bracci PM. Obesity and pancreatic cancer: overview of epidemiologic evidence and biologic mechanisms. Mol carcinog. 2012; 51 (5): 53-63.

72. Wang J, Zhang W, Sun L, Yu H, Ni QX, Risch HA, et al. Dietary Energy Density is Positively Associated with Risk of Pancreatic Cancer in urban Shanshi Chinese. J Nutr. 2013; 143.

73. Ziegler RG, Hoover RN, Nomura AMY, West DW, Wu AH, Fife MC, et al. Relative Weight,Weight Change, Height, and Breast Cancer Risk in Asian-American Women. J Nat Cancer Inst. 1996; 88 (10): 650-60.

74. Pathak DR, Whittemore AS. Combined Effects of Body Size, Parity, and Menstrual Events on Breast Cancer Incidence in Seven Countries. Am J Epidemiol. 1992; 135 (2): 153-68.

75. Ballard-Borbash R. Anthropometry and Breast Cancer. Body Size-A Moving Target. Cancer. 1994; 74 (3suppl): 1090-100.
76. Schapira DV, Clark RA, Wolff PA, Jarrett AR, Kumar NB, Aziz NM. Visceral Obesity and Breast Cancer Risk. Cancer. 1994; 74 (2): 632-9.
77. Zhang S, Folsom AR, Sellers TA, Kushi L, and Potter JD. Better Breast Cancer Survival for Postmenopausal Women Who Are Less Overweight and Eat Less Fat. The Iowa Women’s Health Study. Cancer. 1995; 76 (2): 275-83.
78. Siiteri PK. Adipose Tissue as a Source of Hormones. Am J Clin Nutr. 1987; 45 (1suppl): 277-82.
79. Russo J, Rivera B, Russo IH. Influence of Age and Parity on the Development of the Human Breasts. Breast Cancer Res Treat. 1992; 23 (3): 211-8.
80. Gunter MJ, Leitzmann MF. Obesity and colorectal cancer: epidemiology, mechanisms and candidate genes. J Nutr Biochem. 2005; 17 (3): 145-56.
81. Potter JD. Nutrition and Colorectal Cancer. Cancer Causes Control. 1996; 7 (1): 127-46.
82. Phillips RL, Snowdon DA. Dietary Relationships with Fatal Colorectal Cancer Among Seventh-Day Adventists. J Nat Cancer Inst. 1985; 74 (2): 307-17.
83. Giovannucci E, Ascherio A, Rimm EB, Colditz GA, Stampfer MJ, and Willett WC. Physical Activity, Obesity, and Risk for Colon Cancer and Adenoma in Men. Ann Int Med. 1995; 122 (5): 327-34.
84. Slattery ML, Potter J, Caen B, Edwards S, Coates A, Ma KN, et al. Energy Balance and Colon Cancer—Beyond Physical Activity. Cancer Res. 1997; 57 (1): 75-80.
85. Carroll KK. Obesity as a Risk Factor for Certain Types of Cancer. Lipids. 1998; 33 (11): 1055-9.
86. Lipworth L, Tarone RE, McLaughlin JK. The epidemiology of renal cell carcinoma. J Urol. 2006; 176 (6 Pt 1): 2353-8.
87. Haggstrom c, Rapp K, Stocks T, Manger J, Bjorge T, Ulmer H, et al. Metabolic factors associated with risk of renal cell carcinoma. PLoS One. 2013; 8 (2): e57475.
88. Waalkes S, Mersenburger AS, Karmer MW, Herrmann TRW, Wegener G, Rustemeier J, et al. Obesity is associated with improved survival in patients with organ-confined clear-cell kidney cancer. Cancer Cause Control. 2010; 21 (11): 1905-10.
89. Wolk A, Lindblad P, Adami HO. Nutrition and Renal Cell Cancer. Cancer Cause Control. 1996; 7 (1): 5-18.